DCC-2812
Phase 1Small molecule
DCC-2812 is one of 50 small molecule programs targeting Renal Cell Carcinoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
77 competitors in Renal Cell Carcinoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Lenvima
EisaiPhase 3
Eloxatin
TevaApproved
Inlyta
PPrism Pharmaceuticals
Phase 3
Casodex
IIstituto Clinico Humanitas
Approved
Adrucil
EElorac, Inc.
Approved
Hycamtin
MMeitheal
Approved
IC-Green
PProvepharm SAS
Approved
Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DCC-2812. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- DDeciphera Pharmaceuticals, LLC